Study links immune-cell AP-1 signaling to salt-sensitive blood pressure

Vanderbilt Health on September 7 highlighted research identifying an immune-cell signaling pathway that may help explain why some people’s blood pressure responds strongly to salt. The findings connect AP-1 activity with salt sensitivity and suggest a potential research target for protecting blood vessels and kidneys, although they do not establish an effective treatment for patients.

The study, led by Taseer Ahmad and Annet Kirabo, was published online in Circulation Research on August 17, 2026. This week’s institutional announcement brings renewed attention to that earlier paper. Its relevance to healthspan lies in understanding a cardiovascular risk factor that can occur even in people without established hypertension.

### Connecting human observations with laboratory experiments

The researchers combined experiments in salt-sensitive mice, laboratory studies of human immune cells and an inpatient investigation involving volunteers described as prehypertensive. The human component used controlled salt loading and depletion to distinguish people whose blood pressure was salt-sensitive from those whose pressure was comparatively resistant.

In salt-sensitive participants, salt loading coincided with increased AP-1 gene expression and higher blood pressure. Salt-resistant participants did not show the same concordant response. Experiments also examined how high salt affected monocytes, a type of immune cell.

That human association alone cannot establish that AP-1 causes the blood-pressure response. The team therefore transferred blood immune cells from human donors into immunodeficient mice and measured blood pressure, blood-vessel responses, kidney function and immune-cell infiltration.

Cells from salt-sensitive donors produced more harmful effects than cells from salt-resistant donors. Pretreating the salt-sensitive cells with the AP-1 inhibitor T5224 prevented the reported vascular and kidney dysfunction in this experimental setting. The intervention involved cells used in mouse experiments; it was not a demonstration that administering the inhibitor to patients treats hypertension.

### Why salt sensitivity matters

Salt sensitivity describes variation in blood-pressure responses to sodium exposure. A 2025 review in Nature Reviews Cardiology identifies it as a cardiovascular risk factor in people both with and without hypertension. The review also describes an important diagnostic obstacle: salt loading and depletion procedures used to characterize the condition are difficult to apply in routine clinical practice.

That creates two distinct research needs. Scientists need to understand the biology responsible for differing responses, while clinicians need practical ways to recognize those differences. The AP-1 study addresses the biological question. It does not validate a convenient screening test or establish a threshold that could guide care.

The broader literature also describes differences in salt sensitivity related to sex and hormonal physiology. Any future diagnostic or therapeutic approach would need evaluation across relevant populations before its usefulness could be generalized.

### What remains unanswered

The evidence supports further investigation of a mechanism. It does not show fewer heart attacks, strokes or deaths, nor does it demonstrate longer healthy life. Blood pressure and experimental measures of organ function are informative endpoints, but they cannot substitute for evidence of durable patient benefit.

The accessible abstract and institutional account do not provide the human sample size, detailed participant demographics or numerical effect estimates. Those omissions limit assessment of precision and generalizability. Transferring human cells into mice also reproduces only part of the biology of a person living with cardiovascular risk.

Before AP-1 inhibition could have a clinical role here, researchers would need to establish whether its effects translate to humans, whether benefits persist and whether interference with immune signaling creates unacceptable harms. For now, the study offers a specific biological hypothesis for further testing, with the treatment implications remaining preliminary.